Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%

Study Summary

The purpose of this study is to assess the treatment-related adverse events and associated healthcare resource use in programmed death ligand 1 (PD-L1) negative individuals diagnosed with advanced/metastatic non-small cell lung cancer (NSCLC) who received first-line therapy

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions / Drugs

Nivolumab + ipilimumab Nivolumab + ipilimumab + platinum-based chemotherapy Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy Other dual-immuno-oncology therapy with chemotherapy

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment300 participants

Primary Completion—

Lead SponsorBristol-Myers Squibb

Data Retrieved2026-04-11 04:08:14.746980+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.